Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cancer Manag Res. 2019 Sep 2;11:8095-8100. doi: 10.2147/CMAR.S216675. eCollection 2019.

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.

Author information

1
Apogenix AG, Heidelberg, Germany.

Abstract

Glioblastoma is the most common and aggressive malignant tumor of the central nervous system. Despite the existing high unmet medical needs, the past few decades have seen no notable improvement in overall survival for glioblastoma patients. One active area of research to develop new therapeutic options for this disease is focusing on the CD95/Fas receptor and its ligand CD95L/FasL. It is now recognized that in addition to its role in programmed cell death, CD95/CD95L signaling is involved in a wide range of other apoptotic and non-apoptotic pathways directed toward T-effector cells and cells in the tumor microenvironment involved in tumor progression and invasiveness. Asunercept is a first-in-class recombinant glycosylated fusion protein, which has been designed to selectively bind to CD95L and therefore disrupt CD95/CD95L signaling. The current report provides a brief overview of the role of the CD95/CD95L signaling pathway in cancer pathogenesis and discusses how asunercept was designed to bind and neutralize CD95L and disrupt signaling thereby potentially improving outcomes in glioblastoma and other malignancies.

KEYWORDS:

APG101; CD95/CD95L; apoptosis; asunercept; glioblastoma; immuno-oncology

Conflict of interest statement

AK and CG are full time employees of Apogenix AG. AK was a former Hexal AG employee within the last 36 months. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center